Anti-Hu CD87 PE

*Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007 Nov;92 (11) :1451-9., URL: http://www.ncbi.nlm.nih.gov/pubmed/18024392 , *Lanza F, Castoldi GL, Castagnari B, Todd RF 3rd, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S: Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol. 1998 Oct;103 (1) :110-23., URL: http://www.ncbi.nlm.nih.gov/pubmed/9792297 , *Elghetany MT, Patel J, Martinez J, Schwab H: CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. Cytometry B Clin Cytom. 2003 Jan;51 (1) :9-13., URL: https://www.ncbi.nlm.nih.gov/pubmed/12500292